Clinical Trial Update: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II trial of the DCVAC/PCa dendritic cell vaccine added to hormone therapy in men with metastatic prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DCVAC/PCa (dendritic cell vaccine DCVAC/PCa)

Snippet

Sponsor: SOTIO a.s. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED